[Newsmp] During the last quarter, foreign ownership percentages of 8 out of 47 companies in the KOSPI pharmaceutical index increased by over 1 percentage point.
In contrast, foreign ownership rates of four companies decreased by more than 1 percentage point, leaving only Dong-A ST with a foreign ownership of more than 20%.
HanAll Biopharma's foreign ownership rate increased by 2.60 percentage points in the third quarter, the largest increase among the pharmaceutical index, according to the Korea Exchange.
JW Pharmaceutical increased by 2.35 percentage points, Daewon Pharmaceutical by percentage points, and Daewoong Pharmaceutical by percentage points, with foreign ownership percentages rising by 2 percentage points or more for these four companies.
Moreover, PharmGen Science saw an increase of 1.59 percentage points, JW Life Science 1.55 percentage points, Aprogen Pharmaceuticals 1.51 percentage points, and Dong Wha Pharm 1.05 percentage points, resulting in 8 companies' foreign ownership percentages increased by 1% or more.
The foreign ownership rates of Hyundai Pharmaceutical, Kukje Pharma, Dong-A ST, and Chong Kun Dang Pharmaceutical increased by more than 0.5 percentage points, and Kyongbo Pharmaceutical, Daewoong, Chong Kun Dang Holdings, Handok, Boryung, Yungjin Pharm., CKD Bio, Samsung Pharmaceutical, Reyon Pharmaceutical, and Ilsung Pharmaceutical's foreign ownership also increased slightly.
On the other hand, during the same period, foreign ownership percentages for Gene One Life Science decreased by 2.46%, Whanin Pharmaceutical by 2.35%, Hanmi Pharmaceutical by 1.28%, and Green Cross by 1.22%, with more than a 1% reduction in foreign ownership for these four companies.
Bionote, Yuhan Corporation, Il Dong Holdings, Myungmoon Pharmaceutical, Samil Pharmaceutical, ORIENTBIO, Shin Poong Pharmaceutical, and Il Dong Pharmaceutical saw their foreign ownership ratio decrease by more than 0.5 percentage points.
Furthermore, there were slight declines in foreign ownership percentages for Yuyu Pharma, Samsung Biologics, Korea United Pharm, Pharmicell, Samjin Pharmaceutical, Il-Yang Pharmaceutical, SK Bioscience, Jeil Pharmaceutical, Dongsung Pharmaceutical, Bukwang Pharmaceutical, and Kwang Dong Pharmaceutical.
In the meantime, Dong-A ST had the only foreign ownership of over 20% among the 47 companies at 21.33%, followed by Celltrion at 19.63%, Yuhan Corporation at 18.98%, Kwang Dong Pharmaceutical at 18.62%, and Green Cross at 18.35%.
Hanmi Pharmaceutical and Daewon Pharmaceutical exceeded 15%, at 15.87% and 15.59%, with Gene One Life Science at 14.03%, Whanin Pharmaceutical at 11.06%, JW Pharmaceutical at 10.65%, and Samsung Biologics at 10.24%, recording double digits.
